173897-73-9

Upstream product

• 173898-15-2 (R)-(+)-4-(1-benzyloxycarbonylaminoethyl)-benzoic acid 

Downstream Products

• 173897-74-0 (R)-N-(pyridin-4-yl)-4-(1-benzyloxycarbonylaminoethyl)benzamide 
• 173897-93-3 (R)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-benzyloxycarbonylaminoethyl)benzamide 
• 173897-94-4 (R)-N-(1H-pyrazolo[3,4-b]pyridin-4-yl)-4-(1-benzyloxycarbonylaminoethyl)benzamide 
• 199433-58-4 (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide 
• 471843-75-1 Y-39983 
• 173897-44-4 (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride 

Relevant academic research and scientific papers

VISUAL FUNCTION DISORDER IMPROVING AGENTS

The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-(1H-pyrrolo?2,3-büpyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent

N-heterocyclic substituted benzamide derivatives with antihypertensive activity

Benzamide compounds of the formula wherein each symbol is as defined in the specification, isomers thereof and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions comprising a therapeutically effective amount of this compo

Benzamide compounds and pharmaceutical use thereof

Benzamide compounds of the formula STR1 wherein each symbol is as defined in the specification, isomers thereof and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions comprising a therapeutically effective amount of this